Masimo v. Apple: Federal Circuit Dismissal in Sensor Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Masimo Corp. v. Apple, Inc. |
| Case Number | 24-1625 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB (implied) |
| Duration | Apr 1, 2024 – Jan 16, 2026 1 year 9 months |
| Outcome | Voluntary Dismissal – No Ruling on Merits |
| Patents at Issue | |
| Accused Products | Apple Watch models (optical sensing components) |
Case Overview
The Parties
⚖️ Plaintiff
Global leader in noninvasive patient monitoring technology, holding an extensive portfolio of patents related to pulse oximetry and wearable health sensors.
🛡️ Defendant
Leading consumer electronics company whose Apple Watch series has become a central battleground for health monitoring patents, integrating blood oxygen and optical sensor technologies.
Patents at Issue
At the center of this proceeding was **U.S. Patent No. 7,761,127 B2** (Application No. 11/366,209), directed to a **multiple wavelength sensor substrate**. This patent covers a foundational architecture used in optical sensors that measure biological data — such as blood oxygen saturation — across multiple light wavelengths. This technology is critical to wearable health monitors, including smartwatches.
- • US 7,761,127 B2 — Multiple wavelength sensor substrate
Developing optical health sensors?
Check if your sensor design might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit dismissed the proceeding pursuant to Fed. R. App. P. 42(b) — a voluntary dismissal by stipulation of the parties. The order specified that each side shall bear its own costs, a standard condition in stipulated dismissals that signals a negotiated resolution rather than a clear-cut winner or loser. No damages were awarded, and no injunctive relief was issued at this appellate stage.
Key Legal Issues
The **verdict cause is classified as “Patentability — Invalidity/Cancellation Action,”** indicating that Apple challenged the validity of U.S. Patent No. 7,761,127 B2, likely seeking cancellation of claims through a USPTO trial proceeding with subsequent appeal to the Federal Circuit. A Rule 42(b) dismissal at the appellate level typically reflects a **coordinated resolution across multiple fronts**, rather than an isolated appellate decision. The patent’s survival (or resolution by agreement) at the appellate stage means **U.S. Patent No. 7,761,127 B2 was not conclusively invalidated by this proceeding.** The claims covering the multiple wavelength sensor substrate remain part of Masimo’s enforceable portfolio unless addressed in other proceedings.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in wearable health sensor design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View 47 related patents in the optical sensor technology space
- See which companies are most active in health sensor patents
- Understand claim construction patterns for sensor substrates
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Multiple wavelength sensor substrates
47 Related Patents
In optical sensor design space
Design-Around Options
Available for most sensor claims
✅ Key Takeaways
Rule 42(b) stipulated dismissals at the Federal Circuit reflect strategic portfolio management, not litigation failure.
Search related case law →Invalidity challenges to foundational platform patents carry high appellate costs with uncertain outcomes.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. 7,761,127 B2 (Application No. 11/366,209), directed to a multiple wavelength sensor substrate — core technology in optical health monitoring devices.
The proceeding was dismissed pursuant to Fed. R. App. P. 42(b) by mutual agreement of the parties, with each side bearing its own costs. No judicial ruling on the merits was issued.
The patent survived the appellate proceeding without cancellation, reinforcing its enforceability. Companies developing optical biosensor products should conduct updated FTO analysis against Masimo’s portfolio.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center — U.S. Patent No. 7,761,127 B2
- PACER Federal Court Records
- United States Court of Appeals for the Federal Circuit — Rule 42 Procedures
- U.S. Patent and Trademark Office — Patent Trial and Appeal Board (PTAB)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.